NEW YORK — MedGenome said on Wednesday that it has formed a Parkinson's disease research alliance with Denali Therapeutics.
MedGenome said it will use its database of genetic variants in South Asians — developed through research partnerships, its participation in the GenomeAsia 100K initiative, and its genetic diagnostics business in India — to help Denali identify and analyze genes and variants associated with Parkinson's disease, with the goal of discovering new treatments.
Additional terms of the deal were not disclosed.
"Our collaboration with Denali underscores the untapped potential of genomically under-represented population groups, in particular those from South Asia, with unique population history," Rayman Mathoda, CEO of MedGenome's genomic medicines division, said in a statement.
Earlier this year, Foster City, California-based MedGenome raised $55 million in a private financing round.
This is Denali's second such deal with a genetic diagnostics firm. In 2018, Denali began working with Centogene to recruit patients for a Parkinson's disease drug program.